A Phase II, Double-Blind, Crossover Study to Assess the Efficacy and Safety of 10% (150mg) Lidocaine Vaginal Gel Administered to Women With Recurrent Dysmenorrhea

Trial Profile

A Phase II, Double-Blind, Crossover Study to Assess the Efficacy and Safety of 10% (150mg) Lidocaine Vaginal Gel Administered to Women With Recurrent Dysmenorrhea

Completed
Phase of Trial: Phase II

Latest Information Update: 07 May 2015

At a glance

  • Drugs Lidocaine (Primary)
  • Indications Dysmenorrhoea
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Columbia Laboratories
  • Most Recent Events

    • 29 Sep 2008 Interim results reported in a Columbia media release. Complete analysis of secondary data ongoing.
    • 08 Sep 2008 Status changed from active, no longer recruiting to completed according to Columbia Laboratories media release.
    • 08 Sep 2008 Top-line results available 29 Sep 2008 according to Columbia Laboratories media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top